Digital genome companies are at the forefront of the genomics revolution, specializing in the acquisition, analysis, and interpretation of genomic data through advanced digital technologies. These companies leverage cutting-edge computational and bioinformatics tools to decode and interpret the information contained within an individual's genetic material.
Apr 2023: To enhance its health and service continuum, Beneva is incorporating BiogeniQ's pharmacogenetic tests into its best practices for managing disability and rehabilitation. Therefore, Beneva wants to expand the scope of its healthcare offering to encompass various health conditions, particularly those related to chronic pain, to support its plan members better. It also wants to improve the deployment of this solution by making it more accessible to more Canadians. Adding BiogeniQ's ground-breaking tool to our support plans is a testament to our dedication to offering our covered plan members cutting-edge, compassionate options to enhance their health. Research has demonstrated that by increasing the likelihood of rehabilitation, a customized approach based on pharmacogenomic studies shortens the duration of impairment brought on by long-term illnesses or mental health issues.
A $20 million capital commitment has been made to Genomes.io, a biotech company based in London specializing in the secure monetization of genomic data, by GEM Digital Limited, a digital asset investment corporation established in the Bahamas. According to Genomes.io, the money will be used to boost the company's technological advancement and increase the number of customers who may use its reporting and vault services. With the support, they will be able to democratize the genetics market by utilizing their decentralized technology to make it far more transparent and egalitarian.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)